U.S. President Donald Trump has announced sweeping new tariffs targeting pharmaceuticals and metals, intensifying his trade agenda a year after launching broad duties on global partners. The measures, signed Thursday, aim to pressure drug companies to manufacture in the United States and to counter what officials describe as manipulation of metals prices by foreign producers.
One order imposes a 100-percent tariff on patented pharmaceuticals manufactured abroad unless companies commit to building plants in the U.S. or countries negotiate trade deals to secure lower rates. Large pharmaceutical firms have 120 days to present reshoring plans, while smaller companies have 180 days before the tariff takes effect. Those committing to build facilities by the end of Trump’s second term will face a reduced 20-percent duty.
The European Union, Japan, South Korea, and Switzerland are exempt from the steep tariff due to existing trade agreements, but they will still face a 15-percent duty on pharmaceuticals. Drug makers that agree to “Most Favored Nation” pricing arrangements with Washington and establish U.S. plants can avoid the tariffs altogether. A senior administration official said the policy is designed to ensure “the lion’s share of the world’s patented pharmaceuticals” are produced domestically.
The second order reshapes existing 50-percent tariffs on steel, aluminum, and copper. Importers will now pay duties based on the prices American buyers face, rather than manipulated foreign benchmarks. Finished products containing more than 15 percent of these metals will be subject to a 25-percent tariff on their full value, rather than being taxed only on the metal content. Officials described the change as a simplification intended to ensure fairness.
Trump’s announcement coincided with the anniversary of “Liberation Day,” the date he originally unveiled tariffs on goods from dozens of economies. Those measures disrupted supply chains and rattled financial markets. Although the Supreme Court struck down the global tariffs earlier this year, Trump has sought to reinstate duties through alternative legal authorities.
The President has consistently argued that tariffs are essential to revive American industry, create jobs, and generate investment. Critics, however, contend that the promised economic boom has not materialized and warn that the new measures could raise consumer prices. Administration officials dismissed those concerns, insisting the changes will not affect affordability. “These will not have an impact on the price of the good on the shelf,” one official said.
The pharmaceutical tariffs mark one of Trump’s most aggressive moves yet, reflecting his frustration with reliance on foreign production. By tying exemptions to domestic investment, the administration hopes to accelerate reshoring and reduce vulnerability in critical sectors.
The metals overhaul similarly underscores Trump’s determination to confront what he views as unfair trade practices. By shifting the tariff calculation to full product value, the administration aims to close loopholes and discourage companies from exploiting pricing disparities.
Together, the measures highlight Trump’s continued reliance on tariffs as a cornerstone of his economic strategy. They also signal his willingness to challenge industries and trading partners alike, even as concerns grow about inflation and global supply chain stability.
